Neridronic acid - Abiogen Pharma
Alternative Names: AHBP; AHDP; AHHexBP; Aminohexane diphosphonate; Aminohexane-bisphosphonate; Attila; Neridronate; Neridronate-sodium; NerixiaLatest Information Update: 02 Jan 2023
Price :
$50 *
At a glance
- Originator Istituto Gentili
- Developer Abiogen Pharma; Austin Pain Associates; Grunenthal; Lee's Pharmaceutical; Shire Pharmaceuticals Group
- Class Analgesics; Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Osteitis deformans; Osteogenesis imperfecta
- Registered Complex regional pain syndromes
- Phase III Osteoporosis
- Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis
Most Recent Events
- 02 Jan 2023 Phase III development for Osteoporosis is ongoing in Italy (IV) (EudraCT2018-003505-26)
- 02 Jan 2023 No development reported - Phase-III for Complex regional pain syndromes in Asia (IV)
- 02 Jan 2023 No development reported - Phase-III for Complex regional pain syndromes in European Union (IV)